[1]Fuwai Hospital, Center for Pulmonary Vascular Diseases,Beijing,China
[2]Fuwai Hospital,Beijing,China
[3]Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, Department of Epidemiology and Statistics,Beijing,China
[4]Harbin Medical University, Cardiovascular Department,Harbin,China
[5]Shenyang General Hospital of PLA, Department of Congenital Heart Disease,Shenyang,China
[6]Jining Medical University Affiliated Hospital, Shandong Provincial Key Laboratory of Cardiac Disease Diagnosis and Treatment,,China
[7]Peking Union Medical College, Department of Rheumatology,Beijing,China
[8]First Affiliated Hospital of Kunming Medical University, Department of Cardiology,Kunming,China
[9]Nanjing University, School of Medicine, National Clinical Research Center of Kidney Diseases,Nanjing,China
[10]s Hospital, Department of Ophthalmology,Shanghai,China
[11]an Jiaotong University, Department of Neurology,Xian,China
[12]First Affiliated Hospital of Harbin Medical University, Department of Cardiology,Harbin,China
[13]Shanghai Institute of Cardiovascular Diseases,Shanghai,China
[14]Renji Hospital, Department of Rheumatology,Shanghai,China
[15]Affiliated Hospital of Guangdong Medical University, Cardiovascular Medicine Center,Zhanjiang,China
[16]Guangdong Medical College, Department of Internal Medicine,Zhanjiang,China
[17]Guangxi Medical University, Department of Cardiology,Nanning,China
[18]Guangxi Medical University, Guangxi Medical College,Nanning,China
[19]Zhejiang University School of Medicine, Sir Run Run Shaw Hospital,Hangzhou,China
[20]Zhejiang University, Department of Surgery,Hangzhou,China
[21]Fuwai Hospital, Department of Cardiology,Beijing,China
[22]Fuwai Hospital, State Key Laboratory of Cardiovascular Disease,Beijing,China
[23]Anhui Medical University, Department of Toxicology,Hefei,China
[24]Kunming Medical College,Kunming,China
[25]an Jiaotong University, First Affiliated Hospital,Xian,China
[26]Renji Hospital, Department of Cardiology,Shanghai,China
[27]Capital Medical University China, Department of Cardiology,Beijing,China
[28]Capital Medical University China, Department of Respiratory and Critical Care Medicine,Beijing,China
The impact of sildenafil on pulmonary arterial hypertension (PAH) in Chinese patients has been less investigated. A prospective, open-label, uncontrolled and multicenter study, therefore, was carried out to address this issue. Ninety patients with multicause-induced PAH received oral sildenafil (75 mg/day) for 12 weeks. The 6-minute walk test (SMWT) and cardiac catheterization were performed at the beginning and the end of the 12 weeks. The primary endpoint was the changes in exercise capacity assessed by the SMWT; the secondary endpoint included assessment of functional class, evaluation of cardiopulmonary hemodynamics, and clinical worsening. Drug safety and tolerability were also examined. The results showed that there was a significant improvement in SMWT distances (342 ± 93 m vs 403 ± 88 m, P <.0001), Borg dyspnea score (2.9 ± 2.6 vs 2.4 ± 2.0, P =.0046), World Health Organization functional class, and cardiopulmonary hemodynamics (mean pulmonary artery pressure, P <.0001; cardiac index, P <.0001; pulmonary vascular resistance, P <.0001) after 12 weeks of oral sidenafil therapy. Almost all enrolled patients did not experience significant clinical worsening. This study confirms and extends the findings of previous studies relating to effects of sildenafil on PAH, suggesting that oral sildenafil is safe and effective for the treatment of adult patients with PAH in the Chinese population. © 2012 American College of Clinical Pharmacology, Inc.
(8.0+极速模式)